Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High

PURPOSE: Microsatellite instability-high (MSI-H) colorectal carcinomas (CRCs) show high rates of response to immune checkpoint inhibitors (IOs). B2M mutations and protein loss have been proposed as causes of resistance to IOs, yet they are enriched in MSI-H CRC. We aimed to characterize B2M-mutant,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Main Authors: Middha, Sumit, Yaeger, Rona, Shia, Jinru, Stadler, Zsofia K., King, Sarah, Guercio, Shanna, Paroder, Victoriya, Bates, David D.B., Rana, Satshil, Diaz, Luis A., Saltz, Leonard, Segal, Neil, Ladanyi, Marc, Zehir, Ahmet, Hechtman, Jaclyn F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
Original Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469719/
https://ncbi.nlm.nih.gov/pubmed/31008436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00321
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados